single-antigen-targeted CAR-T cells

Single-antigen-targeted CAR-T cells are a form of adoptive cellular immunotherapy where a patient's T cells are genetically engineered to express a single chimeric antigen receptor (CAR) specific to one tumor-associated antigen. This design is the foundational architecture of CAR-T therapy, contrasting with multi-antigen-targeted (e.g., dual or tandem) CARs. In the treatment of B-cell malignancies, these cells typically target surface proteins such as CD19, CD20, or CD22. The CAR construct typically consists of an extracellular single-chain variable fragment (scFv) for antigen recognition, a transmembrane domain, and intracellular signaling domains (such as CD3-zeta and costimulatory domains like 4-1BB or CD28) that trigger T-cell activation and cytotoxic activity upon binding to the target antigen. In clinical protocols developed by Beijing Boren Hospital, single-antigen CAR-T cells are utilized in sequential infusion strategies following dual-antigen CAR-T cells to improve durable responses and mitigate the risk of relapse due to antigen escape in pediatric patients with relapsed or refractory mature B-cell lymphoma.

Other names

single-target CAR-T cellssingle-antigen CAR-T